NYSE:GSK – US Market Buzz

Is VBI Vaccines, Inc. (NASDAQ:VBIV) The Biotech Stock To Watch In 2016? GlaxoSmithKline (NYSE:GSK)

admin — Mon, 29 Feb 2016 20:28:23 +0000

The markets have been a bit shaky between oil prices evaporating and shareholders looking ahead to testimony from Janet Yellen.
On Monday morning as wary shareholders evaluated China’s transition to speed up its slowing economy and increasing oil prices which have raised hopes that the market has bottomed out. China’s central bank on Monday cut its reserve requirement ratio, or the amount of money that financial institutes must hold as reserves, for the fifth time in a year.

“It’s sort of like a sugar shock, a bump in near-term growth at the expense of longer-term credibility. I think investors are caught weighing the two,” stated Jack Ablin, chief investment officer at BMO.

While markets continue to sanction, there are various stocks to keep an eye on amid recent interaction and groundbreaking advancements; specifically in the biotech sector. In a recent announcement VBI Vaccines, Inc. (NASDAQ:VBIV) entered into a joint research venture with GlaxoSmithKline Biologicals SA, the Belgium-based human vaccine research arm of GlaxoSmithKline (NYSE:GSK). The engagement was entered into a system to have GSK Biologicals asses VBI’s LPV Platform. Being that GSK is putting in the hours to create or enhance current vaccines to cover a wide range of global diseases (including HIV, influenza, malaria, and tuberculosis) this evaluation will give GSK a window in which to option a negotiation of an exclusive licensing agreement on VBI’s LPV Platform for use in a established field.

The majority of GlaxoSmithKline (NYSE:GSK)‘s investigative studies focus on improving the access to vaccines for people in developing countries around the world. GSK Biologicals has teamed up with WHO (world Health Organization) and UNICEF to further its reach into lower economic regions and rid various deadly diseases. GSK Biologicals is also engaged in the worldwide hunt for vaccinations against avian flu and malaria. Being that VBI has verified evidence pertaining to concept research on various vaccines and biologic key points they have been able to display the LPV Platform’s ability to conserve potency under stress conditions. Furthermore, being that GSK is a very well established company, VBI’s LPV is not only limited to new vaccines.

The LPV Platform can be used for either new or current vaccines to maintain stability and potency of several classes of vaccine antigens and biologics, as well as protein-based, monoclonal antibodies, whole-inactivated, and live-attenuated vaccines and viral vectors. The vaccine market has very distinct structure, which increases the difficulty of evaluating and understanding pricing and procurement. It is made up of individual markets for individual vaccines or vaccine types, each with their own specifics. UNICEF Supply Division and PAHO Revolving Fund have considerable influence on the market, which allows them to procure vaccines for significantly lower prices than many countries could achieve on their own.

Every year UNICEF purchases some or all vaccines for up to 100 places around the world whereas PAHO procures for around 40 member states. Going on the connections made between GSK and organizations like UNICEF, VBI’s Platform in the near future could soon be on the high road for deployment by GSK Biologicals; both of which are publicly traded in biotech sector with potential in a bear market.

Bear Market Has Biotech Stocks to Watch For Potential; GlaxoSmithKline plc (ADR) (NYSE:GSK), VBI Vaccines Inc (NASDAQ:VBIV)

admin — Wed, 10 Feb 2016 18:00:27 +0000

The markets have been choppy to say the least amid oil price volatility and investors looking ahead to testimony from Janet Yellen. The Dow Jones industrial average dropped almost 150 points shortly after the open Tuesday morning, but briefly reversed its trend. The blue chips index also briefly rose 100 points in late-afternoon trading, but closed about 12 points lower on Tuesday. Wednesday as rumors build surrounding the Fed’s possible implementation of negative interest rates as a way to boost economic activity, Chair Janet Yellen said the central bank has not completely researched whether that would be legal.

While markets continue to waiver, there are several stocks to pay attention to amid recent engagement and groundbreaking advancements; specifically in biotechnology. In a recent announcement VBI Vaccines Inc (NASDAQ:VBIV) entered into a research collaboration with GlaxoSmithKline Biologicals SA, the Belgium-based human vaccine research arm of GlaxoSmithKline plc (ADR) (NYSE:GSK). The engagement was entered into in order to have GSK Biologicals evaluate VBI’s LPV Platform.

Being that GSK is working to develop or improve vaccines to cover a range of global diseases (including HIV, influenza, malaria, and tuberculosis) this evaluation will allow GlaxoSmithKline plc (ADR) (NYSE:GSK) a period in which to option a negotiation of an exclusive licensing agreement of VBI’s LPV Platform for use in a defined field.

Much of GSK’s research focuses on increasing vaccine access to developing countries. GSK Biologicals has partnered with WHO (world Health Organization) and UNICEF to extend its reach into poorer regions and eliminate disease. GSK Biologicals is also involved with the worldwide search for vaccinations against avian flu and malaria.

Being that VBI Vaccines Inc (NASDAQ:VBIV) has completed proof of concept studies on a number of vaccine and biologic targets they have been able to demonstrate the LPV Platform’s ability to preserve potency under stress conditions. Furthermore, being that GSK is a very well established company, VBI’s LPV is not solely limited to new vaccines.

The LPV Platform can be used for either new or existing vaccines to preserve stability and potency of several classes of vaccine antigens and biologics, including protein-based, monoclonal antibodies, whole-inactivated, and live-attenuated vaccines and viral vectors.

The vaccine market has very distinct features, which increase the complexity of assessing and understanding pricing and procurement. It is made up of individual markets for individual vaccines or vaccine types, each with their own specificities. UNICEF Supply Division and PAHO Revolving Fund have considerable influence on the market, which allows them to procure vaccines for significantly lower prices than many countries could achieve on their own. Annually UNICEF procures some or all vaccines for up to 100 countries whereas PAHO procures for around 40 member states. Based on the relationships built between GSK and organizations like UNICEF, VBI’s Platform could soon be on a fast track for deployment by GSK Biologicals; both biotech stocks with potential in a bear market.

About Biotech Stocks (www.BiotechStocks.com)
Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.

Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. BiotechStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. BiotechStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. BiotechStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Contact Info:
Email:info@biotechstocks.com
URL: www.BiotechStocks.com

Biotech Figurehead Endorsing the Little Guys; SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF), Opko Health Inc. (NYSE:OPK), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), GlaxoSmithKline plc (ADR) (NYSE:GSK)

admin — Mon, 19 Oct 2015 20:10:44 +0000

Though weakness in China, volatile commodity prices and increasing concerns over the health of the U.S. economy have had an opposing impact on capital markets and have caused a number of market participants to sit out, healthcare companies continue to be active. Experts don’t believe macro fears will impact M&A. David Blume, Co-founder and Managing Director at Edgemont Capital stated, “I feel healthcare will be more resilient than most sectors, because the fundamentals that are driving M&A in healthcare aren’t as sensitive to overall macro-economic factors,” He continued with, “What’s driving M&A activity in pharma is the challenge of bringing new products to market in a cost effective way. Companies that are cash rich and product poor are looking for access to products, and use lower cost capital and cash reserves in order to do so.” Healthcare began 2015 on strong note, seeing $95.3 billion worth of deals in the first quarter of 2015, amounting for 12% of all the merger and acquisitions, seeing a 70% increase year over year. Next in the first half of 2015 the pharmaceutical sector saw approximately $221 billion in deals, almost three times the amount for the first six months of 2014. “Pharmaceutical companies have to buy, especially in the biotech arena for fear of their pipelines drying,” said Afsaneh Naimollah, Partner at Marlin & Associates. He concluded with, “The pharmaceutical companies have to consolidate not only for cost synergies, but to get their patent portfolios fortified.”

In today’s world, there are over 400 million people infected with hepatitis in all its forms. Last year, there were 1.3 million deaths recorded. And the world’s deadliest form of hepatitis is Hepatitis B, with over 240 million infections and approximately 780,000 deaths per year. This brings us to a biotech company that is looking to take the hepatitis B market by storm, SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF). SciVac Therapeutics, Inc, has already begun to attract the big players such as former Chariman of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and current CEO and Chairman of Opko Health Inc. (NYSE:OPK) Philip Frost. About a month ago Philip Frost closed an agreement with SciVac that brought the company public and immediately available to investors. The company’s flagship product hepatitis B (HBV) vaccine is called SciVac’s Sci-B-Vac has already been approved in 10 countries globally, and is proven to be 98% effective. If that’s not enough the vaccine has been shown to be 100% effective on newborns that were administered the treatment. The treatment has already been tested in 20 separate clinical trials on more than 5,000 patients.

Dr. Phillip Frost, states, SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) intends to pursue marketing approvals for Sci-B-Vac in the United States and other territories worldwide, initially focusing on at-risk populations such as End-Stage Renal Disease and HIV patients.” The company has a market cap of almost 150 million with current sales of about $10 million annually in vaccine. If by any chance Sci-B-Vac can successfully infiltrate pharma giant GlaxoSmithKline plc (ADR) (NYSE:GSK) vaccine Engerix market of over $1 billion a year to even 30%, that then equates to $300 million in sales annually for SciVac. With the proper support from biotech figurehead like Dr. Frost along evidence from clinical trials I think it’s fair to say SciVac’s vaccine has the potential of wiping hepatitis B from existence.

About SciVac Therapeutics Inc.
SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. The Company’s flagship product, Sci‐B‐Vac, is a recombinant 3rd generation hepatitis B vaccine. The Company is also developing an early-stage enzyme-based product designated S-Graft, which is a recombinant human deoxyribonuclease I, a repurposed biological therapeutic intended for the prevention and treatment of graft-versus-host disease (GVHD). The Company also offers contract development and manufacturing services to the life sciences and biotechnology markets.